-+ 0.00%
-+ 0.00%
-+ 0.00%

Jamjoom Pharma Partners with Mubadala Bio for Inflammation Drug Distribution in UAE

MT Newswires·10/23/2026 00:58:01
语音播报
12:58 AM EDT, 10/23/2026 (MT Newswires) -- Jamjoom Pharmaceuticals Factory Co. (SASE:4015) agreed to serve as the exclusive commercial partner for Mubadala Bio unit Bioventure Healthcare's chronic inflammation drug Ustekinumab in the United Arab Emirates. The Saudi drugmaker will oversee compliant product commercialization and engagement with healthcare professionals in compliance with applicable regulatory requirements, according to a Thursday release.